Department of Biomedical Engineering, Texas A&M University, Mailstop 3120, College Station, TX, 77843-3120, USA.
CorInnova, Incorporated, Houston, TX, USA.
J Cardiovasc Transl Res. 2019 Apr;12(2):155-163. doi: 10.1007/s12265-018-9854-5. Epub 2019 Jan 2.
While the number of patients supported with temporary cardiac assist is growing, the existing devices are limited by a multitude of complications, mostly related to contact with the blood. The CorInnova epicardial compressive heart assist device was tested in six sheep using an acute heart failure model. High esmolol dose, targeting a 50% reduction in CO from healthy baseline, resulted in a failure state with mean CO 1.9 L/min. Heart assist with the device during failure state resulted in an average absolute increase in CO of 1.0 L/min, along with a decline in ventricular work to 67.5% of the total LV SW. Combined with repeated success of minimally invasive device implant, the resulting increases in cardiac hemodynamics achieved while still unloading the heart demonstrate the potential of the CorInnova device for temporary heart assist.
虽然支持临时心脏辅助的患者数量在不断增加，但现有的设备受到多种并发症的限制，这些并发症主要与血液接触有关。CorInnova 心外膜压缩式心脏辅助装置在六只绵羊中使用急性心力衰竭模型进行了测试。高剂量艾司洛尔，目标是将 CO 从健康基线降低 50%，导致平均 CO 为 1.9 L/min 的衰竭状态。在衰竭状态下使用该设备进行心脏辅助，平均绝对 CO 增加 1.0 L/min，心室做功下降至左心室总 SW 的 67.5%。结合微创设备植入的多次成功，在减轻心脏负荷的同时实现的心脏血液动力学的增加，证明了 CorInnova 设备用于临时心脏辅助的潜力。
